Quellenverzeichnis

Devinsky O, Cross JH, Laux L, et al: Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376:2011-2020.
Zuardi AW, Rodrigues NP, Silva AL, et al: Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol 2017;8:259.
Bergamaschi MM, Queiroz RH, Chagas MH, et al: Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011;36:1219-1226.
Leweke FM, Piomelli D, Pahlisch F, et al: Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2:e94.
Carlini EA, Cunha JM: Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 1981;21(suppl):417S-427S.
Morgan CJ, Das RK, Joye A, et al: Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 2013;38:2433-2436.
Chagas MH, Zuardi AW, Tumas V, et al: Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J Psychopharmacol 2014;28:1088-1098.
Hoch, E., Friemel, C. M. & Schneider, M. (2018). Cannabis: Potenzial und Risiko. https://doi.org/10.1007/978-3-662-57291-7